| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.048 | 0.8 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.043 | 0.8 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |